Podium Bio Ltd. has described compounds acting as apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, ...
Maze Therapeutics Inc. has identified apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic, hypertensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results